Capfin India Ltd

Capfin India Ltd has announced the closure of its trading window for dealings in the company's securities. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 1, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. This measure is standard practice to prevent insider trading during periods when material non-public information may be available.

Capfin India Ltd. reports no deviation or variation in the utilization of funds raised through a preferential issue of equity shares, as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The funds, amounting to ₹338.66 lakhs, were raised on March 31, 2026, and were intended to augment financial resources for working capital and general corporate purposes. The Audit Committee reviewed and confirmed the absence of any deviation. Auditors also had no comments.

Capfin India Ltd. announced the appointment of Mr. Umesh Kumar Sahay as the Chairperson of the Company, effective May 11, 2026. Additionally, M/s. Sachapara & Associates were appointed as Secretarial Auditor and M/s. Dhirubhai Shah & Co LLP as Internal Auditor for the FY 2026-27.

Capfin India Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, along with the auditor's report with an unmodified opinion from M/s. Mehra Goel & Co. The board also appointed Mr. Umesh Kumar Sahay as Chairperson, M/s. Sachapara & Associates as Secretarial Auditor for FY 2026-27, and M/s. Dhirubhai Shah & Co LLP as Internal Auditor for FY 2026-27. The board meeting commenced at 05:25 P.M. (IST) and concluded at 6:00 P.M. (IST).

Capfin India Ltd. announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 11, 2026. M/s. Mehra Goel & Co., Chartered Accountants, issued an Audit Report with an unmodified opinion. The Board meeting commenced at 05:25 P.M. (IST) and concluded at 6:00 P.M. (IST).

Capfin India Ltd has scheduled a meeting of its Board of Directors on May 11, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The company has informed the BSE about this meeting in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Capfin India Ltd's Management Committee approved the allotment of 5,80,000 fully paid-up equity shares on a preferential basis. The shares, with a face value of ₹10 each, were issued at an issue price of ₹32.88 per share, including a premium of ₹22.88. This allotment successfully raised ₹1,90,70,400 for the company. The shares were allotted to four investors, including members of the promoter/promoter group, and will rank pari-passu with existing equity shares.

Capfin India Ltd has announced a preferential allotment of 8,80,000 equity shares to Abhishek Narbaria, Umesh Kumar Sahay, and Sixth Venture Advisors LLP. This allotment is for cash consideration and increases the holding of these acquirers in the company. The equity share capital of the company will increase from Rs. 2,93,82,300 to Rs. 3,96,82,300 after the allotment.

Capfin India Ltd has allotted 10,30,000 fully paid-up equity shares of face value of Rs. 10 each, at an issue price of Rs. 32.88 per Equity Share including a premium of Rs. 22.88 per Equity Share. The allotment has been made on a preferential basis to persons including the promoter/promoter group, for cash consideration. The allotted Equity Shares shall rank pari-passu, in all respects with existing equity shares of the Company.

Capfin India Ltd's Jagdish Umakant Nayak has disclosed the purchase of 9,600 equity shares of Clinitech Laboratory Limited, a company listed on the Bombay Stock Exchange. This acquisition was made on March 30, 2026, and it increases his holding to 0.42% of the total share/voting capital of the company. This disclosure was made under Regulation 29 (2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011.